PURPOSE: This study evaluated the usefulness of the maximum standardized uptake value (SUVmax) as a measure of histologic response to neoadjuvant chemotherapy in patients with extremity osteosarcoma. The correlation between [(18) F]FDG PET SUVmax values and histologic response to preoperative chemotherapy was also assessed prospectively using PET/MRI. METHODS: A total of 26 consecutive patients with high-grade osteosarcoma were prospectively enrolled. All patients underwent parallel PET and MRI scans before and after neoadjuvant chemotherapy. Using the PET and MRI images and pathologic mapping, we assessed the percentage necrosis by histology at the highest metabolic activity point in the tumors. This was defined as the minimum histologic response. The predictive values of SUVmax before (SUV1) and after (SUV2) chemotherapy and the SUV change ratio were determined. Correlations were also investigated among SUV2, minimum histologic response and histologic response. RESULTS: Histologically, 13 patients were classified as good responders and 13 as poor responders. Patients with an SUV2 of >5 showed a poor histologic response. A significant correlation was found between SUV2 and histologic response (Spearman's rho -0.642; P < 0.001), and SUV2 and histologic response were both found to be significantly correlated with minimum histologic response (Spearman's rho -0.515 and 0.911; P = 0.007 and P < 0.001, respectively). CONCLUSION: A SUVmax of more than 5 after neoadjuvant chemotherapy identified the majority of histologic nonresponders (sensitivity 61.3 %, PPV 88.9 %). Tumor necrosis at the point of maximum metabolic activity was found to be significantly correlated with the histologic response of entire resected specimen.
PURPOSE: This study evaluated the usefulness of the maximum standardized uptake value (SUVmax) as a measure of histologic response to neoadjuvant chemotherapy in patients with extremity osteosarcoma. The correlation between [(18) F]FDG PET SUVmax values and histologic response to preoperative chemotherapy was also assessed prospectively using PET/MRI. METHODS: A total of 26 consecutive patients with high-grade osteosarcoma were prospectively enrolled. All patients underwent parallel PET and MRI scans before and after neoadjuvant chemotherapy. Using the PET and MRI images and pathologic mapping, we assessed the percentage necrosis by histology at the highest metabolic activity point in the tumors. This was defined as the minimum histologic response. The predictive values of SUVmax before (SUV1) and after (SUV2) chemotherapy and the SUV change ratio were determined. Correlations were also investigated among SUV2, minimum histologic response and histologic response. RESULTS: Histologically, 13 patients were classified as good responders and 13 as poor responders. Patients with an SUV2 of >5 showed a poor histologic response. A significant correlation was found between SUV2 and histologic response (Spearman's rho -0.642; P < 0.001), and SUV2 and histologic response were both found to be significantly correlated with minimum histologic response (Spearman's rho -0.515 and 0.911; P = 0.007 and P < 0.001, respectively). CONCLUSION: A SUVmax of more than 5 after neoadjuvant chemotherapy identified the majority of histologic nonresponders (sensitivity 61.3 %, PPV 88.9 %). Tumor necrosis at the point of maximum metabolic activity was found to be significantly correlated with the histologic response of entire resected specimen.
Authors: Linda M Velasquez; Ronald Boellaard; Georgia Kollia; Wendy Hayes; Otto S Hoekstra; Adriaan A Lammertsma; Susan M Galbraith Journal: J Nucl Med Date: 2009-09-16 Impact factor: 10.057
Authors: Andrea A Martoni; Claudio Zamagni; Sara Quercia; Marta Rosati; Nicoletta Cacciari; Alessandra Bernardi; Alessandra Musto; Stefano Fanti; Donatella Santini; Mario Taffurelli Journal: Cancer Date: 2010-02-15 Impact factor: 6.860
Authors: Gi Jeong Cheon; Min Suk Kim; Jun Ah Lee; Soo-Yong Lee; Wan Hyeong Cho; Won Seok Song; Jae-Soo Koh; Ji Young Yoo; Dong Hyun Oh; Duk Seop Shin; Dae-Geun Jeon Journal: J Nucl Med Date: 2009-08-18 Impact factor: 10.057
Authors: Colleen M Costelloe; Homer A Macapinlac; John E Madewell; Nancy E Fitzgerald; Osama R Mawlawi; Eric M Rohren; A Kevin Raymond; Valerae O Lewis; Peter M Anderson; Roland L Bassett; Robyn K Harrell; Edith M Marom Journal: J Nucl Med Date: 2009-03 Impact factor: 10.057
Authors: James C Davis; Najat C Daw; Fariba Navid; Catherine A Billups; Jianrong Wu; Armita Bahrami; Jesse J Jenkins; Scott E Snyder; Wilburn E Reddick; Victor M Santana; M Beth McCarville; Junyu Guo; Barry L Shulkin Journal: J Nucl Med Date: 2017-06-13 Impact factor: 10.057